BiotechTube

Dipraglurant

Phase 2/3Terminated
0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Parkinson Disease

Conditions

Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias

Trial Timeline

Oct 25, 2021 → Aug 15, 2022

NCT ID
NCT05116813

About Dipraglurant

Dipraglurant is a phase 2/3 stage product being developed by Addex Therapeutics for Parkinson Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05116813. Target conditions include Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson Disease were approved

Approved (20) Terminated (3) Active (0)
✅Mirabegron + PlaceboAstellas PharmaApproved
✅Lemborexant + placeboEisaiApproved
✅Safinamide MesilateEisaiApproved
✅Istradefylline PillKyowa KirinApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅Carbidopa/levodopa/entacaponeNovartisApproved
✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

Hype Score Breakdown

Clinical
15
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05116813Phase 2/3Terminated

Competing Products

20 competing products in Parkinson Disease

See all competitors
ProductCompanyStageHype Score
exidavnemab + Placebo ComparatorBioArctic ABPhase 2
36
UB-312 + PlaceboVaxxinityPhase 1
19
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
22
LY4006896 + PlaceboEli LillyPhase 1
36
ATH-1017 + PlaceboLeonaBioPhase 2
17
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
35
Mirabegron + PlaceboAstellas PharmaApproved
43
E2007EisaiPhase 3
32
ARICEPTEisaiPhase 3
40
PerampanelEisaiPhase 3
32
GPI 1485EisaiPhase 2
35
E2007EisaiPhase 3
40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
40
Equfina 50 mgEisaiPre-clinical
26
EqufinaEisaiPre-clinical
26
perampanel + placeboEisaiPhase 2
27
Lemborexant + placeboEisaiApproved
50
Placebo + E2007 + E2007EisaiPhase 3
32
Safinamide MesilateEisaiApproved
43
E2007 + E2007 + E2007EisaiPhase 2
35